/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy
Event: ESC Congress 2023
Topic: Antidiabetic Pharmacotherapy
Session: Novel targets and treatments for heart diseases and diabetes
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
Event: ESC Congress 2022
Topic: Antidiabetic Pharmacotherapy
Session: Anti-diabetic pharmacotherapy in clinical practice
Risk of heart failure associated with thiazide diuretics compared with calcium channel blockers in patients with type 2 diabetes: a nationwide nested case-control study
Event: ESC Congress 2020
Topic: Prevention
Session: Pharmacological Interventions To Treat and Prevent Acute Heart Failure
Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies
Event: ESC Congress 2019
Topic: Epidemiology
Session: The right glucose-lowering drugs for the right patient
Development of heart failure in type 2 diabetes: ischemic heart disease, end stage renal disease or hypertension and diabetes? a nationwide cohort study
Event: ESC Congress 2018
Topic: Epidemiology, Prognosis, Outcome
Session: Heart failure: the nemesis of Diabetes
ESC 365 is supported by
